Pub. Date : 2021 Jan
PMID : 33037135
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist. | bi 905711 | cadherin 17 | Homo sapiens |
| 2 | BI 905711 is a novel tetravalent bispecific antibody targeting both TRAILR2 and CDH17 and represents a novel liver-sparing TRAILR2 agonist specifically designed to overcome the disadvantages of previous strategies. | bi 905711 | cadherin 17 | Homo sapiens |
| 3 | Here, we show that BI 905711 effectively triggered apoptosis in a broad panel of CDH17-positive CRC tumor cells in vitro. | bi 905711 | cadherin 17 | Homo sapiens |
| 4 | BI 905711 demonstrated single-agent tumor regressions in CDH17-positive CRC xenografts, an effect that was further enhanced upon combination with irinotecan. | bi 905711 | cadherin 17 | Homo sapiens |
| 5 | BI 905711 induced apoptosis in both a cis (same cell) as well as trans (adjacent cell) fashion, translating into significant anti-tumor activity even in xenograft models with heterogeneous CDH17 expression. | bi 905711 | cadherin 17 | Homo sapiens |
| 6 | In summary, we demonstrate that BI 905711 has potent and selective antitumor activity in CDH17-positive colorectal cancer models both in vitro and in vivo. | bi 905711 | cadherin 17 | Homo sapiens |
| 7 | The high prevalence of over 95 percent CDH17-positive tumors in CRC patients, the molecule preclinical efficacy together with its potential for a favorable safety profile, support the ongoing BI 905711 phase I trial in CRC and additional CDH17-positive cancer types (NCT04137289). | bi 905711 | cadherin 17 | Homo sapiens |